REC-PFC merger clears President's nod; Micro-cap governance red flags pile up

The President has cleared the merger of REC into PFC, creating a combined ₹10 lakh crore lending entity that will dominate power-sector finance. The consolidation forces a revaluation of both stocks against a single, much larger balance sheet, but the share-exchange ratio, the number that determines who got the better deal, remains undisclosed. Until that lands, the merger is a headline without a price.

Concord Biotech has won USFDA approval for Tofacitinib tablets, tapping a $500M U.S. market that is nearly four times its FY26 revenue. This comes on the back of a 30% profit decline in the year just ended, making the approval a genuine turnaround catalyst if even modest market share materialises. The zero-debt balance sheet gives Concord room to invest behind the launch, but the supply-chain headwinds that crushed FY26 still need to fully unwind.

Meta has committed to 900 MW of Indian clean power through CleanMax, a deal projected to generate ₹450-500 crore in annual revenue, roughly a quarter of the company's FY26 sales. After landing a 160 MW hybrid deal with Gujarat Alkalies and commissioning 351 MW in Rajasthan, the Meta partnership is the execution proof that opens doors with other hyperscalers. The risk is counterparty concentration in a single customer, but for a platform selling clean power to data centres, this is the contract that validates the model.

Afcons Infrastructure has landed a ₹5,301 crore breakwater contract at Vadhvan Port, equal to 44% of its annual revenue and 45% of its market cap. This is the kind of sovereign-backed order that locks in multi-year earnings visibility for a company that just posted its first quarterly loss since 2010 and refused to guide for FY27. The scale is large, but so is the execution risk for a contractor still digesting ₹260-265 crore in provisions.

Alembic Pharmaceuticals has secured sole Paragraph IV status on generic Larotrectinib, giving it 180 days of exclusivity in a $91 million U.S. cancer drug market. The approval adds a meaningful oncology asset to a pipeline that already delivered a Synthroid launch into a $1.87 billion market. With FY27 revenue guidance of low double-digit growth and ₹750-800 crore in R&D spend, the pipeline machine keeps compounding.

Vascon Engineers has landed its largest-ever order, a ₹347.43 crore government contract worth 47% of its market cap, with a 36-month execution window. For a company with a -34.62% revenue decline and -83.21% PAT growth in its last reported period, this is a scale-change in revenue visibility. The open question is whether a micro-cap with a ₹805 crore market cap can execute a project this large without straining its balance sheet.

Esaar India wants to raise ₹60 crore through a rights issue, which is 2.5 times its own ₹24 crore market cap. Six days ago, the company was still 'weighing' the proposal; now it has cleared the ceiling without disclosing the rationale or the price. For a company whose revenue growth was 751% last year off a tiny base, the raise will either massively dilute shareholders or inject capital that dwarfs the business it funds.

Harbhole Agrotech has filed a Section 9 insolvency petition against Evoq Remedies, a company with a ₹7 crore market cap, effectively zero revenue and a going-concern qualification already in place. The filing came on April 22 but was disclosed only now, a two-month lag that adds another governance red flag to a company whose auditor already flagged unconfirmed related-party loans. This is not a procedural hurdle; it is likely the beginning of the end.

Esha Media Research wants to borrow ₹50 crore, nearly triple its ₹18 crore market cap, and is seeking ratification for undisclosed past borrowing. The company carries a going-concern qualification and a negative net worth of -₹10.4 crore, making this a restructuring-level event rather than growth financing. For a nano-cap with these numbers, the request for retroactive approval is the real headline.

Kalyani Forge's CFO has resigned at a company where auditors have refused to sign off on the books for three consecutive years. Baheti was the finance head during the period of disclaimers, and no successor has been named. The delayed disclosure, combined with a ₹218 crore market cap carrying record profit on paper but unverified inventory and trade balances, turns a routine departure into a governance test.

AstraZeneca India has won CDSCO approval for Enhertu in first-line HER2 breast cancer, expanding the label for a drug that generated over $3 billion globally last year. The approval positions Enhertu in the frontline setting where treatment durations are longer and volumes are higher, building on a year where AstraZeneca India's revenue grew 33% on oncology launches. This widens the addressable market for the company's highest-profile franchise.

Dhruv Consultancy has landed a ₹19.34 crore railway contract, equal to 36.5% of its market cap and its fourth order win since late May. The 36-month project breaks Dhruv out of its narrow highway consultancy niche and deepens a pattern of government infrastructure awards flowing to nano-cap service providers. The revenue visibility is genuine; the execution capacity at this scale is the question.

GNG Electronics' promoter must sell 3.95% of equity, roughly ₹177 crore worth of stock, to meet SEBI's 25% minimum public-float rule, after the company's post-IPO lock-up left promoter holding at 78.71%. This is a forced seller with a mid-2026 deadline, not a voluntary exit. For a ₹4,777 crore small-cap with a 1.97x debt-to-equity ratio, the overhang is real and the timing is the promoter's only lever.

CARE has downgraded Vishnu Prakash R Punglia to junk status after the company reported a ₹156 crore cash loss in FY26, nearly half its ₹314 crore market cap. The two-notch downgrade into sub-investment-grade territory follows non-cooperation with the rating agency, which the company blames on a procedural dispute. CARE's data on collections and promoter pledging suggests the disagreement is about more than paperwork.